Marina Ulanova

External Website:

Marina Ulanova Infection & Immunology Lab Website

Research Interests

Researcher and professor at the Northern Ontario School of Medicine in the Medical Sciences Division.           Dr. Ulanova's group works on a number of projects related to infection and immunology. Areas of research include clinical immunology, epidemiology, vaccinology, health issues in northern and indigenous communities, and basic science studies of host-pathogen interactions.

Selected Publications

Characterization of natural bactericidal antibody against Haemophilus influenzae type a in Canadian First Nations: A Canadian Immunization Research Network (CINR) Clinical Trials Network (CTN) study.
Nix EB, Choi J, Anthes C, Gaultier GN, Thorgrimson J, et al. Characterization of natural bactericidal antibody against Haemophilus influenzae type a in Canadian First Nations: A Canadian Immunization Research Network (CIRN) Clinical Trials Network (CTN) study. PLOS ONE 2018. 13(8): e0201282.

Epidemiology of invasive pneumococcal disease in the city of Kenora, Ontario, Canada and surrounding area (2010-2016).
Eton V, Ulanova M. Epidemiology of invasive pneumococcal disease in the city of Kenora, Ontario, Canada and surrounding area (2010-2016). JAMMI, Official Journal of the Association of Microbiology and Infectious Disease Canada. 2018. (in press).
​
Recurrent meningitis caused by Streptococcus pneumoniae serotype 15C associated with Wiskott-Aldrich syndrome.
Eton V, Beveridge J, Ulanova M. Recurrent meningitis caused by Streptococcus pneumoniae serotype 15C associated with Wiskott-Aldrich syndrome. JAMMI, Official Journal of the Association of Microbiology and Infectious Disease Canada. 2018; 3.2:114-117. doi: 10.3138/jammi.2017-0007.

Design, synthesis and immunological evaluation of novel amphiphilic desmuramyl peptides.
Khan F, Ulanova M, Bai B, Damayanthi, Y, Jiang Z-H. Design, synthesis and immunological evaluation of novel amphiphilic desmuramyl peptides. European Journal of Medicinal Chemistry. 2017 Sept 30; 141:26-36. doi: 10.1016/j.ejmech.2017.09.070.

Syk inhibitor R406 down-regulates inflammation in an in vitro model of Pseudomonas aeruginosa infection.
Alhazmi A, Choi J, Ulanova M. Syk inhibitor R406 down-regulates inflammation in an in vitro model of Pseudomonas aeruginosa infection.  Can J Physiol Pharmacol. 2017 Oct 11. doi: 10.1139/cjpp-2017-0307.

Epidemiology of invasive pneumococcal and Haemophilus influenzae diseases in Northwestern Ontario, Canada, 2010-2015.
Eton V, Schroeter A, Kelly L, Kirlew M, Tsang RSW, Ulanova M. Epidemiology of invasive pneumococcal and Haemophilus influenzae diseases in Northwestern Ontario, Canada, 2010-2015.  Int J Infect Dis. 2017 Sep 22;65:27-33. 
​
The immunostimulatory capacity of nontypeable Haemophilus influenzae lipooligosaccharide.
Gaultier GN, Colledanchise KN, Alhazmi A, Ulanova M. The immunostimulatory capacity of nontypeable Haemophilus influenzae lipooligosaccharide. Pathogens and Immunity, 2017, 2 (1): 34-49.

Editorial: The emerging Haemophilus influenzae serotype a infection and a potential vaccine: Implementation science in action.
Barreto L, Cox D, Ulanova M, Bruce MG, Tsang RSW. Editorial: The emerging Haemophilus influenzae serotype a infection and a potential vaccine: Implementation science in action. Can Commun Dis Rep. 2017;43(5):85-88.

Developing a vaccine for Haemophilus influenzae serotype a: Proceedings of a workshop.
AD Cox, L Barreto, M Ulanova, MG Bruce, RSW Tsang on behalf of the Conference Contributors. Developing a vaccine for Haemophilus influenzae serotype a: Proceedings of a workshop. Can Commun Dis Rep. 2017;43(5):89-95.

The changing epidemiology of invasive Haemophilus influenzae disease: emergence and global presence of serotype a strains that may require a new vaccine for control.
Tsang RSW and Ulanova M. The changing epidemiology of invasive Haemophilus influenzae disease: emergence and global presence of serotype a strains that may require a new vaccine for control. Vaccine. 2017 Jul 24;35(33):4270-4275. 

Paediatric meningococcemia in Northwestern Ontario, Canada: a case for publicly funded meningococcal B vaccination.
Eton V, et al. Paediatric meningococcemia in Northwestern Ontario, Canada: a case for publicly funded meningococcal B vaccination. JMM Case Rep 2016 3. doi: 10.1099/jmmcr.0.005017

Haemophilus influenzae type a as a cause of pediatric septic arthritis.
Thorgrimson J and Ulanova M. Haemophilus influenzae type a as a cause of pediatric septic arthritis. JMM Case Rep 2016 3 doi:10.1099/jmmcr.0.005064 

Dynamics of naturally acquired antibody against Haemophilus influenzae type a capsular polysaccharide in a Canadian Aboriginal population.
Konini A, Nix E, Ulanova M, Moghadas SM. Dynamics of naturally acquired antibody against Haemophilus influenzae type a capsular polysaccharide in a Canadian Aboriginal population. Prev Med Rep. 2016 Jan 26;3:145-50. 

Naturally occurring bactericidal antibodies specific for Haemophilus influenzae lipooligosaccharide are present in healthy adult individuals.
Choi J, Nix EB, Gaultier GN, Cox AD, McCready W, Ulanova M. Naturally occurring bactericidal antibodies specific for Haemophilus influenzae lipooligosaccharide are present in healthy adult individuals. Vaccine. 2015 Apr 15;33(16):1941-7.

Naturally acquired antibodies against Haemophilus influenzae type a in Aboriginal adults, Canada.
Nix EB, Williams K, Cox AD, St Michael F, Romero-Steiner S, Schmidt DS, McCready WG, Ulanova M. Naturally acquired antibodies against Haemophilus influenzae type a in Aboriginal adults, Canada. Emerg Infect Dis. 2015 Feb;21(2):273-9. 

Hospital admission for community acquired pneumonia in a First Nations population.
Poling J, et al. Hospital admission for community acquired pneumonia in a First Nations population. Can J Rural Med. 2014 Fall; 19 (4): 135-41

A review of invasive Haemophilus influenzae disease in the Indigenous populations of North America.
Tsang RS, Bruce MG, Lem M, Barreto L, Ulanova M. A review of invasive Haemophilus influenzae disease in the Indigenous populations of North America. Epidemiol Infect. 2014 Jul;142(7):1344-54. 
​
Activation of innate immune responses by Haemophilus influenzae lipooligosaccharide.
Choi J, Cox AD, Li J, McCready W, Ulanova M. Activation of innate immune responses by Haemophilus influenzae lipooligosaccharide. Clin Vaccine Immunol. 2014 May;21(5):769-76. 

Haemophilus influenzae serotype a as a cause of serious invasive infections.
Ulanova M and, Tsang RSW.  Haemophilus influenzae serotype a as a cause of serious invasive infections. Lancet Infectious Diseases 2014 Jan;14(1):70-82

Emergence of non-type b encapsulated Haemophilus influenzae as a cause of pediatric meningitis in Northwestern Ontario.
Sadeghi-Aval P, et al. Emergence of non-type b encapsulated Haemophilus influenzae as a cause of pediatric meningitis in Northwestern Ontario. Can J Infect Dis Med Microbiol 2013, 24 (1):13-16

Neglected infectious disease in Aboriginal communities: Haemophilus influenzae serotype a and Helicobacter pylori.
Ulanova M, et al.  Neglected infectious disease in Aboriginal communities: Haemophilus influenzae serotype a and Helicobacter pylori. Vaccine 2012, 30: 6960-6

Invasive disease caused by Haemophilus influenzae type a in Northern Ontario First Nations communities. 
Kelly L, et al. Invasive disease caused by Haemophilus influenzae type a in Northern Ontario First Nations communities. J Med Microbiol 2011, 60: 384-390